|
KMID : 0882420100790040394
|
|
Korean Journal of Medicine
2010 Volume.79 No. 4 p.394 ~ p.403
|
|
|
Clinical outcomes of erlotinib, gefitinib, or pemetrexed in patients with non-squamous, non-small-cell lung cancer
|
|
Yoon La-Young
Yang Mi-Yean
Yun Jin-A
Kim Hyun-Jung
Kim Han-Jo
Kim Kyoung-Ha
Kim Se-Hyung
Lee Sang-Cheol
Kim Chan-Kyu
Lee Nam-Su
Park Sung-Kyu
Lee Kyu-Taek
Won Jong-Ho
Park Hee-Sook
Hong Dae-Sik
|
|
|
Abstract
|
|
|
Background/Aims: This study compared the clinical benefits of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) with pemetrexed to identify the clinical parameters that correlated with response.
Methods: A retrospective chart review examined patients who were 1) treated with EGFR TKI or pemetrexed, 2) diagnosed with advanced non-squamous non-small-cell lung cancer, and 3) previously treated with platinum-based chemotherapy in Soonchunhyang Bucheon Hospital.
Results: Sixty-one patients (18 erlotinib, 18 gefitinib, 25 pemetrexed) were investigated from February 2002 to August 2009.
The median follow-up period was 37 months (7~97 months). Overall, their median age was 63 years, 41 patients were non-smokers, 57 patients had adenocarcinoma, and 55 patients were at stage IV. Twenty-one patients received the study drugs as second-line chemotherapy, and others as third-line or more. No significant differences in the overall response rate (erlotinib 33.3% vs. gefitinib 38.9% vs. pemetrexed 20.0%) and progression-free survival (erlotinib 1.9 months vs. gefitinib 3.0 months vs. pemetrexed 2.9 months) were found among the three groups. Female gender was related to a good response to EGFR TKIs (p=0.047). Skin rash in the erlotinib group (p=0.037) and adenocarcinoma in the pemetrexed group (p=0.02) were related to improved progression-free survival. Few side effects were reported.
Conclusions: Both EGFR TKIs and pemetrexed therapy for non-squamous non-small-cell lung cancer were efficient and tolerable after the failure of first-line platinum-based chemotherapy. Further prospective studies are needed to validate the predictive role of the suggested clinical parameters in this study.
|
|
|
KEYWORD
|
|
|
Carcinoma, Non-small-cell lung cancer, Erlotinib, Gefitinib, Pemetrexed
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|